Erik Nordkamp – Managing Director, Pfizer UK
Erik Nordkamp, managing director of Pfizer UK shares his thoughts on the future of healthcare and the role that Pfizer and the UK can play in shaping it. He explains…
Pfizer has a rich heritage of working within the UK since our first facility was opened back in 1952.
Over the past 69 years, we have continued to invest in the UK and are committed to working with the NHS and other healthcare organisations across the industry developing solutions to improve the delivery of care and patient outcomes.
We support the NHS Long Term Plan‘s ambition for prevention, empowering people to control their own health, harnessing new technologies and improving the quality of patient care and health outcomes. We believe these are key to help ensure a sustainable NHS and gives the government, the NHS and the pharmaceutical industry the chance to form a new relationship, truly working together to meet these challenges head-on while putting patients first.
In 2020, we spent over £295 million supporting research and development carried out in the UK and contributed to 126 collaborations with universities, pharmaceutical companies, industries and others. Through collaborations with scientists, academics and clinicians, sharing knowledge, skills and expertise we aim to improve the health and lives of people in the UK and around the world. During 2020, we had 36 clinical trials on-going in the UK, across 69 UK sites, involving over 977 patients since the trials started.
The company provides medicines to help treat a variety of serious and life–threatening conditions. With the combined portfolios and resources of Wyeth and Pfizer, Specialty Care has grown substantially. The business unit’s current portfolio includes more than 20 medicines in 12 disease areas, and the pipeline contains more than 25 compounds and indications in Phases II and III. Specialty Care holds leadership positions in vaccines and disease areas such as inflammation, infectious disease, hemophilia and ophthalmology. Neuroscience, Gastroenterology, Women’s Health, Infectious Diseases and Immunology.
Prescription medicines (top 50): Lipitor (1), Lyrica (15), Viagra (26), Xalatan (36).
Contact:
Headquarters: Walton Oaks, Dorking Rd, Tadworth KT20 7NS, Reino Unido
Tel: +44 (0)1304 616161, 0345 608 8866
Erik Nordkamp, managing director of Pfizer UK shares his thoughts on the future of healthcare and the role that Pfizer and the UK can play in shaping it. He explains…
As part of a panel discussion with Claudia Hammond of the BBC last year, you commented on the fairly poor relationship between the NHS and industry, and the need to…
From the perspective of international pharmaceuticals developers, Latin America can be considered a region of exceptional potential owing to solid market fundamentals and significant untapped opportunities. “I am convinced that…
When it comes to pharmaceutical exports, Latin America has historically been confined to the margins of the global life science industry. In 2023, the region accounted for a mere one…
Has Argentina, for years one of the economic basket cases of Latin America, finally turned a corner? And is its pharma industry set for a bounce back? Firebrand TV…
From cancer treatments to cardiovascular drugs, access to innovative medicines in South America lags behind developed market norms with patients forced to endure considerable delays for therapies that are already…
Vaccination remains the most powerful public health intervention ever devised, preventing an estimated 4.4 million deaths each year, according to the WHO. Yet with misinformation spreading faster than science, and…
Sinan Atlig reflects on a 25-year global career spanning Turkey, Colombia, the Middle East, and the US, shaped decisively by vaccine leadership through the COVID-19 era. He identifies vaccines and…
Puerto Rico’s healthcare system is a paradox of strength and fragility. With one of the highest insurance coverage rates in the US (around 94 percent) and a long tradition of…
France is experiencing its biggest pharmaceutical manufacturing boom in decades, with global giants like Novo Nordisk, Sanofi, and Pfizer committing over EUR 4 billion in new investments since 2023. This…
At a time when the pharmaceutical industry faces increasing complexity and scrutiny, Javier Deida, Country Lead of Pfizer Puerto Rico, is spearheading a quietly transformative effort on the island. With…
Saudi Arabia’s pharmaceutical sector continues its impressive growth leadership within the region. With a 9.1 percent market growth in 2024 and a projected USD 11.6 billion in sales, the Kingdom…
Thanks to its strategic location and pro-business environment, Singapore has established itself as a major pharma manufacturing hub in the Asia-Pacific region. Five Big Pharma companies have stepped up their…
In the latest chapter of the trade disputes launched by Donald Trump, the US president has accused Ireland of “stealing” pharma tax revenue. The country’s low corporate tax rates have…
See our Cookie Privacy Policy Here
